All News

Article

Evolution of GCA Treatments - More to Come

Meral K. El Ramahi, MD, FACP, FACR Nov 08, 2020

The field of Rheumatology is an ever-nascent field with an incredible expansion in our therapeutic armamentarium over the past half century. An example of such advancement is easily appreciated when reflecting on the innovative treatment approach to Giant Cell Arteri

Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038. @rheumnow @DrPujaMehta1 #ACR20 Abstr#L06 #ACRbest https://t.co/MTuH0sAuWt

Novel predictors of early mortality in a cohort of GCA pts from Portugal: 🚩Older age at dx 🚩Tongue claudication 🚩Prior tx w/ anticoag BP treatment at dx - predictor of early survival. @RheumNow #ACR20 abs1935 https://t.co/TGJNnZ8vTQ

Dr Benard reports an SLR and meta-analysis of 27 studies comparing 2 rituximab regimes in AAV. 375mg x4 and 1000mg x2 equivalent. Remission in 91% vs 85%. Similar adverse event rates @rheumnow #ACR20 Abstr#2048 https://t.co/I0feVuZ8iy

Dr Sanchez-Bilbao reports a study of 30 patients with LV GCA. Despite clinical remission with tocilizumab ongoing vascular inflammatory activity identified by PET in 70%. Significant implications for risk of tocilizumab withdrawal. @rheumnow #ACR20 Abstr#1921 https://t.co/f1isidSypn

Tocilizumab in GCA: what happens in the vessels? Supporting excellent work @KQuinnRheum @petercgrayson earlier at #ACR20, LV-GCA data from Blanco/Gonzalez-Gay et al. Aorta still hot at 10.8±3.7 mo. in LV-GCA on TCZ, clinical remission ≠ PET remission #ACR20 ABST1921 @RheumNow https://t.co/ngBVL4rop8

High #bloodpressure, jaw claudication and temporal artery abnormalities on palpation associated with increased risk of serious ischaemic events in #GCA, incl visual loss and #CVA. #MSK symptoms including PMR are protective. Abs#1944 #ACR20 @RheumNow https://t.co/sTeql8py9r

Predictors of Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis…

SLR of frequency of visual ischaemia (VI) in relapse & follow-up of GCA -VI >4weeks after GCA diagnosis is uncommon -VI occurs in up to 3% patients with at least one relapse -VI reported 3.5x more in RCTs vs retrospective studies Abs#1929 #ACR20 @RheumNow https://t.co/OztFRZ9VHc

Visual Ischemia During Relapse and Follow-up of Giant Cell Arteritis: A Systema…

This is a great pearl from John Stone. Rapid bedside detection of nasal septal perforation in GPA. Shine light in on nostril, if you see it like this in the other then septum is perforated #ACR20 @rheumnow https://t.co/aecwAWqxOz

#Ulcer on lateral portion of mid-#tongue ➡️Giant Cell Arteritis #GCA ➡️#Granulomatosis with polyangiitis #GPA #Wegeners #Rheumatology pearl by Dr Stone #ACR20 #GiantCellArteritis #vasculitis https://t.co/gTBQVescg9

Looking forward to learning lots of #rheumatology "pearls and myths" in this session by Prof. John Stone #ACR20 @RheumNow https://t.co/p6vKd8DZLI

COVID-19 changes everything, but our vasculitis patients particularly have had some really difficult decisions to make. @VasculitisFound @michaelgeorgemd @maferradastrong @petercgrayson @RADoctor @DrPeterMerkel et al #ACR20 ABST1416 @RheumNow https://t.co/lWXtgSqDqy

We're getting better at treating vasculitis over time. In-hospital mortality in pts primarily admitted with vasculitis is got much closer to all-comers 1998-2014 (US NIS). Hopefully with more new meds, we've closed the gap even more since! @UABRheum #ACR20 ABST1423 @RheumNow https://t.co/kNq8HCjqQ0

Dr. Jas Singh has shown theres been a decline In-Hospital Mortality in Vasculitis patients over 17 yrs (1998-2014) (using NIS data) #ACR20 Abst#1423 @jasvindermd https://t.co/rMJX5lRrLY https://t.co/aE2rJrMdDh

https://meet.acrconvergence.org/meetings/virtual/f4THnkckQDBmX5bEK

National Inpatient Sample claims: ANCA Assoc vasculitis pts hospitalized with acute MI (AMI) had a no increase in mortality rate (5.3% vs. 4.7%) during 2016-2017, suggesting potentially better control w/ new meds (RTX), less steroids #ACR20 Abstr#1424 https://t.co/TYELUAjm9d

https://meet.acrconvergence.org/meetings/virtual/wPtHfjt3Hp4fXBvcn

Great poster-abstract 1260- chicken or egg- what comes first cognitive issues for patients with SLE then the Depression/anxiety or the opposite—-mental health is so important to address!! @RheumNow #ACR20 https://t.co/3ippKQN7Ap

4S013: Rheum Secrets and Pearls - Dr. Stone gives high yield vasculitis pearls. Always characterize by vessels size, get down to fat for adequate skin bx. #ACR20 @RheumNow https://t.co/WTzb9LsO6q

Time-trends analysis of in-hospital mortality in #vasculitis in the US shows it to have significantly declined in this population from 1998 to 2014. Abs#1423 #ACR20 @RheumNow https://t.co/TTI4DJiCRk

Declining In-Hospital Mortality in Vasculitis: A 17-year U.S. National Study - …

Patients diagnosed w/ #ANCA #vasculitis aged >75yrs have lower risk of relapse than pts 65-75yrs. Pts >75yrs less likely to be treated w/ immunosuppression & steroids but do benefit from this treatment when it is required. Abs#1417 #ACR20 @RheumNow https://t.co/stTAcioiQG

Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older…

Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study https://t.co/Z91MhXJ5HK #gca #tocilizumab #pet what about the radiation?

Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor t…

Topics

All News

Evolution of GCA Treatments - More to Come

Do you get our email newsletter?